SHMT1 C1420T polymorphism contributes to the risk of non-Hodgkin lymphoma: evidence from 7309 patients.
- Author:
Yi-Wei WANG
1
;
Shao-Dan ZHANG
2
;
Wen-Ji XUE
3
;
Mei-Ling ZHU
4
;
Lei-Zhen ZHENG
5
Author Information
- Publication Type:Journal Article
- MeSH: Case-Control Studies; Evidence-Based Medicine; methods; Genetic Predisposition to Disease; Glycine Hydroxymethyltransferase; genetics; Humans; Lymphoma, Non-Hodgkin; genetics; Neoplasm Proteins; genetics; Polymorphism, Single Nucleotide; Publication Bias; Sensitivity and Specificity
- From:Chinese Journal of Cancer 2015;34(12):573-582
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDSerine hydroxymethyltransferase 1 (SHMT1) is a key enzyme in the folate metabolic pathway that plays an important role in biosynthesis by providing one carbon unit. SHMT1 C1420T may lead to the abnormal biosynthesis involved in DNA synthesis and methylation, and it may eventually increase cancer susceptibility. Many epidemiologic studies have explored the association between C1420T polymorphism and the risk of non-Hodgkin lymphoma (NHL), but the results have been contradictory. Therefore, we performed this meta-analysis to evaluate the relationship.
METHODSThe meta-analyses were conducted to evaluate the effect of SHMT1 C1420T polymorphism on NHL risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association.
RESULTSEight studies encompassing 3232 cases and 4077 controls were included. A statistically significant association was found between SHMT1 C1420T polymorphism and NHL risk under the allelic comparison (T vs. C: OR = 1.09, 95% CI 1.01-1.17); a borderline association was found between SHMT1 C1420T polymorphism and NHL risk under the homozygote model (TT vs. CC: OR = 1.18, 95% CI 1.00-1.39) and the dominant model (CT+TT vs. CC: OR = 1.10, 95% CI 1.00-1.21).
CONCLUSIONSHMT1 C1420T polymorphism may be associated with NHL risk, which needs to be validated in large, prospective studies.
